January 22, 2018 / 7:13 AM / in 9 months

BRIEF-Genmab Gets USD 50 Mln From Novartis For Lost Potential Milestones And Royalties​

Jan 22 (Reuters) - GENMAB:

* ANNOUNCES NOVARTIS’ INTENTION TO TRANSITION ARZERRA® (OFATUMUMAB) FROM COMMERCIAL AVAILABILITY TO LIMITED AVAILABILITY VIA COMPASSIONATE USE PROGRAMS FOR THE TREATMENT OF CLL IN NON-US MARKETS

* ‍RECEIVES USD 50 MILLION FROM NOVARTIS AS PAYMENT FOR LOST POTENTIAL MILESTONES AND ROYALTIES​

* ‍AMOUNT WILL BE INCLUDED IN GENMAB'S 2018 GUIDANCE​

* ‍ROYALTIES WILL CONTINUE TO BE EARNED ON NET SALES OF ARZERRA​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below